Skip to main navigation
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Contact
  • Pipeline
    • Overview
    • Herpesviruses
    • Viral Hepatitis
    • Research & Discovery
    • Publications
  • Patients
    • Commitment
    • Resources
    • Clinical Studies
  • Sustainability
    • Overview
    • Business Ethics
    • Access to Health Care
    • Human Capital
    • Environment, Health & Safety
  • Collaborations
  • Investors
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financials & Filings
    • Stock Information
  • Careers
    • Culture
    • Benefits
    • Opportunities
On the

Investor Relations

Corporate Profile

Assembly Bio aspires to deliver innovative small molecule antiviral therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide.

Minimum 15 minutes delayed. Source: LSEG

Press Releases

See all news
  • Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
  • Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
  • Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026

Events &
Presentations

See all upcoming events
  • May 27 - May 30, 2026
    European Association for the Study of the Liver (EASL) Congress 2026
  • May 13, 2026 at 4:35 PM PDT
    Bank of America Global Health Care Conference 2026
  • Apr 17 - Apr 21, 2026
    Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
Shareholder Tools Print Email Alerts RSS News Feeds
Search Investors

Contact Us

833.509.4583 info@assemblybio.com LinkedIn
AssemblyBio logo
 
Privacy Notice Cookie Policy

© 2026 Assembly Biosciences, Inc.